| Mar'20 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 | |
|---|---|---|---|---|---|---|
License revenue | ||||||
- | 26,741 | - | - | - | - | |
Operating expenses: | ||||||
Cost of license revenue | ||||||
- | 2,500 | - | - | - | - | |
Research and development | ||||||
68,225 | 55,278 | - | 44,853 | 31,148 | - | |
General and administrative | ||||||
34,262 | 23,495 | - | 18,899 | 10,308 | - | |
Total operating expenses | ||||||
102,487 | 81,273 | - | 63,752 | 41,456 | - | |
Loss from operations | ||||||
-102,487 | -54,532 | - | -63,752 | -41,456 | - | |
Other income (expense), net: | ||||||
Interest income | ||||||
1,941 | 2,736 | - | 2,107 | 528 | - | |
Interest expense | ||||||
4,010 | 2,113 | - | 1,671 | 1,156 | - | |
Loss from ML Bio asset acquisition | ||||||
- | 416 | - | - | - | - | |
Share in net loss of an equity method investment | ||||||
- | -6,589 | - | -4,599 | - | - | |
LEO call option income (expense) | ||||||
- | 276 | - | - | - | - | |
Other income (expense) | ||||||
474 | -26 | - | -1,521 | 6 | - | |
Total other income (expense), net | ||||||
-1,595 | -6,132 | - | -5,684 | -622 | - | |
Net loss | ||||||
-104,082 | -60,664 | - | -69,436 | -42,078 | - | |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | ||||||
-12,232 | -684 | - | -8,251 | -10,677 | - | |
Net loss attributable to common stockholders of BridgeBio | ||||||
-91,850 | -59,980 | - | -61,185 | -31,401 | - | |
Net loss per share, basic and diluted | ||||||
-0.78 | -0.51 | - | -0.66 | -0.52 | - | |
Weighted-average shares used in computing net loss per share, basic and diluted | ||||||
117,803 | 117,071 | - | 92,330 | 60,950 | - | |
BridgeBio Pharma LLC | ||||||
Research and development | ||||||
- | - | 52,331 | - | - | 23,892 | |
General and administrative | ||||||
- | - | 16,918 | - | - | 10,891 | |
Total operating expenses | ||||||
- | - | 69,249 | - | - | 34,783 | |
Loss from operations | ||||||
- | - | -69,249 | - | - | -34,783 | |
Interest income | ||||||
- | - | 1,662 | - | - | 2 | |
Interest expense | ||||||
- | - | 1,941 | - | - | 205 | |
Loss from PellePharm | ||||||
- | - | -4,956 | - | - | - | |
LEO call option income (expense) | ||||||
- | - | 226 | - | - | - | |
Other income (expense) | ||||||
- | - | -7 | - | - | -716 | |
Total other income (expense), net | ||||||
- | - | -5,016 | - | - | -919 | |
Net loss and comprehensive loss | ||||||
- | - | -74,265 | - | - | -35,702 | |
Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | ||||||
- | - | -8,370 | - | - | -9,151 | |
Net loss and comprehensive loss attributable to BridgeBio | ||||||
- | - | -65,895 | - | - | -26,551 | |
Cumulative returns on redeemable convertible preferred units (Series A, Series B and Series C) | ||||||
- | - | - | - | - | 3,854 | |
Net loss attributable to redeemable founder units and redeemable common units | ||||||
- | - | -65,895 | - | - | -30,405 | |
Net loss per unit attributable to redeemable founder unitholders and redeemable common unitholders, basic and diluted | ||||||
- | - | -3.46 | - | - | -1.71 | |
Total weighted-average redeemable founder units and redeemable common units used in computing net loss per unit, basic and diluted | ||||||
- | - | 19,033 | - | - | 17,821 | |